Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TLR4 | O00206 | 4/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11312946 | 0.90 | CHRM2 (0.36) | ALDH1A1TP53MAPTMAPK1CHRM2 | |
| SCHEMBL11316954 | 0.75 | CHRM2 (0.39) | ALDH1A1TP53MAPTMAPK1CHRM2 | |
| SCHEMBL7334201 | 0.73 | CHRM2 (0.44) | ALDH1A1TP53MAPTMAPK1CHRM2 | |
| SCHEMBL9057642 | 0.73 | ALDH1A1 (0.33) | ALDH1A1TP53MAPTMAPK1CHRM2 | |
| SCHEMBL9057639 | 0.73 | ALDH1A1 (0.33) | ALDH1A1TP53MAPTMAPK1CHRM2 | |
| SCHEMBL8463145 | 0.73 | ALDH1A1 (0.36) | ALDH1A1TP53MAPTMAPK1CHRM2 | |
| Hydrochloric Acid SCHEMBL8323044 | 0.72 | ALDH1A1 (0.33) | ALDH1A1TP53MAPTMAPK1CHRM2 | |
| Hydrochloric Acid SCHEMBL8323042 | 0.72 | ALDH1A1 (0.33) | ALDH1A1TP53MAPTMAPK1CHRM2 | |
| Hydrochloric Acid SCHEMBL8464473 | 0.72 | ALDH1A1 (0.33) | ALDH1A1TP53MAPTMAPK1CHRM2 | |
| SCHEMBL7766882 | 0.72 | ALDH1A1 (0.35) | ALDH1A1TP53MAPTMAPK1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086762-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS AG (CH) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086762-A1 | BETA-LACTAMASE INHIBITORS | MGAM, LCT, GAA | ALDH1A1 683/4885TP53 3799/4885MAPT 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.